Travere Therapeutics Inc (TVTX): Next-Year EPS Estimate 1268.42%
As of 2026-06-18, Travere Therapeutics Inc (TVTX) has a next-year EPS growth estimate of 1268.42%. Featured in 2 EPS revision reports, most recently on 2026-04-15.
On 2026-06-18, analyst consensus for TVTX's next-year EPS growth shifted from 1151.86% to 1268.42% — a positive change of 116.56 percentage points. Current-year growth is projected at 161.26%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 1268.42%
- EPS growth this year
- 161.26%
- EPS next quarter (est)
- -$0.08
- Last price
- $55.15
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-18 | 1268.42% | 161.26% | -$0.08 | $55.15 |
| 2026-06-17 | 1151.86% | 168.73% | -$0.08 | $54.14 |
| 2026-06-16 | 1151.86% | 168.73% | -$0.08 | $53.38 |
| 2026-06-15 | 1151.86% | 168.73% | -$0.08 | $53.80 |
| 2026-06-14 | 985.42% | 180.06% | -$0.05 | $52.04 |
| 2026-06-11 | 985.42% | 180.06% | -$0.05 | $48.91 |
| 2026-06-10 | 985.42% | 180.06% | -$0.05 | $46.74 |
| 2026-06-09 | 985.42% | 180.06% | -$0.05 | $48.57 |
| 2026-06-08 | 985.42% | 180.06% | -$0.05 | $47.08 |
| 2026-06-07 | 985.42% | 180.06% | -$0.05 | $45.81 |
| 2026-06-04 | 985.42% | 180.06% | -$0.05 | $46.18 |
| 2026-06-03 | 645.53% | 216.32% | -$0.05 | $45.20 |
| 2026-06-02 | 645.53% | 216.32% | -$0.05 | $42.96 |
| 2026-06-01 | 645.53% | 216.32% | -$0.05 | $45.04 |
| 2026-05-31 | 645.53% | 216.32% | -$0.05 | $47.18 |
| 2026-05-28 | 645.53% | 216.32% | -$0.05 | $47.76 |
| 2026-05-27 | 660.70% | 216.61% | -$0.05 | $47.76 |
| 2026-05-26 | 660.70% | 216.61% | -$0.05 | $44.29 |
| 2026-05-25 | 660.70% | 216.61% | -$0.05 | $44.43 |
| 2026-05-24 | 660.70% | 216.61% | -$0.05 | $44.43 |
| 2026-05-21 | 660.70% | 216.61% | -$0.05 | $44.74 |
| 2026-05-20 | 660.70% | 216.61% | -$0.05 | $43.49 |
| 2026-05-19 | 660.70% | 216.61% | -$0.05 | $42.26 |
| 2026-05-18 | 660.70% | 216.61% | -$0.05 | $42.89 |
| 2026-05-17 | 660.70% | 216.61% | -$0.05 | $42.59 |
| 2026-05-14 | 636.10% | 215.60% | -$0.05 | $44.10 |
| 2026-05-13 | 636.10% | 215.60% | -$0.05 | $44.48 |
| 2026-05-12 | 636.10% | 215.60% | -$0.05 | $42.84 |
| 2026-05-11 | 636.10% | 215.60% | -$0.05 | $43.51 |
| 2026-05-10 | 636.10% | 215.60% | -$0.05 | $42.60 |
Reports Featuring TVTX
Recent News
- Four Biotech Stocks Near Buy Points As Earnings Season Kicks InInvestor's Business Daily
Screen Performance
Aggregate stats across all 1795 tickers our top-EPS-revision screen has flagged over the past 78 days.
- Median return since detection
- +3.6%
- % of tickers in the green
- 58%
- Median return on winners
- +19.9%
- Large revisions captured
- 842
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Travere Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-06-18, Travere Therapeutics Inc (TVTX) has a next-year EPS growth estimate of 1268.42%, based on analyst consensus.
When was the latest EPS estimate revision for TVTX?▾
The most recent revision occurred on 2026-06-18, when analysts adjusted the next-year EPS growth estimate from 1151.86% to 1268.42%.
What sector and industry does Travere Therapeutics Inc belong to?▾
Travere Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. TVTX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Travere Therapeutics Inc (TVTX) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports